The potential value of microseminoprotein-β as a prostate cancer biomarker and therapeutic target

Keyphrases

• Therapeutic Target 100%
• Prostate Cancer 100%
• Cancer Therapeutics 100%
• Prostate Cancer Biomarker 100%
• Benign Prostate Disorders 100%
• β-microseminoprotein 100%
• Amino Acids 50%
• Protein Family 50%
• Genome-wide Association Study 50%
• Cell Surface 50%
• Prostate Cancer Progression 50%
• Prostate Cancer Screening 50%
• SNP 50%
• Apoptosis 50%
• Normal Prostate 50%
• Prostate Tissue 50%
• Cell Growth 50%
• Potential Therapeutics 50%
• Prostate Cancer Development 50%
• Tumourigenesis 50%
• Therapeutic Implications 50%
• 5′-untranslated Region (5′-UTR) 50%
• Cysteine-rich Secretory Protein 50%
• Tissue Biomarkers 50%
• Short Peptides 50%
• Laminin Receptor 50%
• Therapeutic Interventions 50%
• Protein Products 50%
• Recurrent Prostate Cancer 50%

Biochemistry, Genetics and Molecular Biology

• Amino Acids 100%
• Protein Family 100%
• Genome-Wide Association Study 100%
• Single Nucleotide Polymorphism 100%
• Programmed Cell Death 100%
• Carcinogenesis 100%
• Cell Growth 100%
• Tumor Marker 100%
• Laminin 100%
• Cysteine-Rich Secretory Protein 100%
• Peptide 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Tumor Marker 100%
• Biological Marker 50%
• Base 25%
• Amino Acid 25%
• Recurrent Disease 25%
• Carcinogenesis 25%
• Cysteine 25%
• Secretory Protein 25%
• Prostate Protein 25%
• Laminin Receptor 25%
• Peptide 25%